solute carrier family 31 member 1Genealiases: COPT1 · CTR1 · NSCT
Q-omics provides the consensus-scored SLC31A1 profile across patient tissues and cancer cell-line models. SLC31A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC31A1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SLC31A1 protein abundance shows 29,845 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, BLCA, and PDAC as cancer lineages where SLC31A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC31A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC31A1 survival associations across molecular data types. SLC31A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC31A1 RNA expression–survival associations across cancer types. High SLC31A1 expression shows unfavorable associations in ACC, MESO, BLCA, HNSC and ESCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC31A1 RNA expression.
This table summarizes SLC31A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in BRCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC31A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC31A1 shows lower tumor expression in THCA and KIRC and higher tumor expression in BLCA, BRCA, STAD and UCEC. The BLCA box plot shows higher SLC31A1 RNA expression in tumor versus normal tissue (log2 FC = +1.162, t-test p < 0.001).
This table shows molecular features associated with SLC31A1 in patient tissues and cancer cell lines. In patient samples, SLC31A1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC31A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
